Study of efficacy and safety of nilotinib in paediatric CML patients

• Research type

  Research Study

• Full title

  A multi-center, open label, non-controlled phase II study to evaluate efficacy and safety of oral nilotinib in pediatric patients with newly diagnosed Ph+ chronic myelogenous leukemia (CML) in chronic phase (CP) or with Ph+ CML in CP or accelerated phase (AP) resistant or intolerant to either imatinib or dasatinib

• IRAS ID

  135821

• Contact name

  Pamela Kearns

• Contact email

  p.r.kearns@bham.ac.uk

• Sponsor organisation

  Novartis Pharma Services AG

• Eudract number

  2013-000200-41

• REC name

  London - Bloomsbury Research Ethics Committee

• REC reference

  13/LO/1608

• Date of REC Opinion

  20 Jan 2014

• REC opinion

  Further Information Favourable Opinion